Eli Lilly and Company ( NYSE: LLY) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Lucas Montarce - CFO Mike Czapar - SVP, IR ...

And sorry for the few-minute delay. I'm Tim Anderson, a large-cap and U.S. pharma analyst and biotech analyst at Bank of America. We're excited to have Johnson & Johnson with us today ...

Thanks for joining us. I’m Tim Anderson, the U.S. large cap pharma and biotech analyst of Bank of America and excited to have Gilead with us today, specifically Johanna Mercier, who serves as ...

in our opinion," BofA Securities analyst Tim Anderson wrote in a note to clients Thursday. The overarching concern with the CVS/Novo Nordisk deal is whether this starts a race to the bottom on ...

Tariffs, executive orders, FTC probes are just some of the problems piling up for the pharmaceutical industry. Trump's ...

Recently, BofA’s four-star-rated analyst Tim Anderson reiterated a Buy rating on LLY stock, forecasting a growth rate of over 20%. Anderson’s Buy rating reflects the company’s strong growth ...

A rich history of a bygone era in Anderson County is on display in the town of Rocky Top, originally known as Coal Creek. A unique museum shows what life was like when ...

BofA Securities analyst Tim Anderson told Yahoo Finance that the market had overreacted to the news. "I think its going to become more and more known that this is a lot of hype. And what Novo has ...

Healthcare used to be considered a safe, constant growth sector, weighted heavily in some 401(k)s. But it isn't immune to ...

AbbVie stock was on the move after the pharmaceutical company announced the approval of a new cancer drug. The drug, EMRELIS, received accelerated approval from the Food and Drug ...